Cervical Cancer
Conditions
Brief summary
In sub-Saharan Africa, cervical cancer is the leading cause of cancer death among women because of the difficulty in implementing screening programs. The main obstacles in these countries are poverty, lack of healthcare infrastructures and trained practitioners. With the availability of new technologies, researchers are looking for new strategies adapted to low- and middle-income countries to identify cervical precancerous lesions. Current evidence shows that Human Papilloma Virus (HPV) testing is more effective than cytology (Pap smear) for cervical cancer screening in resource-limited settings. Indeed, the GeneXpert® HPV test offers the opportunity to prevent cervical cancer (CC) in a single visit: rapid detection of high-risk HPV (HPV) infection followed by same day treatment of HPV-positive women during the same visit (screen-and-treat approach). However only a small proportion of HPV-positive women will develop cervical (pre)cancer, making it important to select those to treat. This triage can be achieved by colposcopy, cytology and visual inspection after application of acetic acid (VIA). Though VIA is the triage test recommended by WHO for resource-limited countries, it has not yet been widely assessed in sub-Saharan Africa (SSA). The main objective of the investigators is to assess the performance of HPV-test followed by Visual Inspection after application of Acetic acid and Lugol's iodine VIA/VILI to detect cervical precancerous lesions in a screen-and-treat strategy in Cameroon (sub-Saharan Africa) where there is no cervical cancer-screening program. The investigators organized a successful free screening campaign in Cameroon in 2015 that allowed to identify the expectations of women and their eagerness to benefit from prevention of gynecological cancers and sexually transmitted diseases.
Interventions
DIAGNOSTIC_TESTHPV Test
Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators. Two transport mediums will be used for those self-collected vaginal samples: NaCl 0.9%.
Sponsors
Prof. Patrick Petignat
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
* Women aged 30-49 years, able to comply with the study protocol
Exclusion criteria
* Pregnancy * Previous total hysterectomy * Conditions impairing examination of the cervix
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity and specificity of HPV test followed by VIA/VILI to detect cervical precancerous lesions in sub-Saharan Africa using histology as gold standard | 3 - 5 years | VIA/VILI is assessed by pelvic examination and Sensitivity and specificity are measured by using histology as gold stantard |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of cervical pre-cancer and cancer among Cameroonian women | 3 - 5 years | Histological analyses of cervical biopsies and endocervical brushing |
| HPV clearance | 3 - 5 years | Measured by self HPV performed at 6 and 12 months follow up |
| Persistance of CIN2+ disease at the 12-month follow-up | 3 - 5 years | Histological analyses of cervical biopsies and endocervical brushing |
| Provide teaching material for professional training on cervical cancer prevention through VIA/VILI (cervical images database) | 3 - 5 years | images database |
| Acceptability rate of self-HPV test and cervical cancer screening procedures | 3 years | To assess the acceptability of self-HPV, patients complete a questionnaire comprising different questions about the collection device (embarassment, comfort, anxiety and confidence about the test). Likert Scale 4 points : 1 (not at all) to 4 (very). |
| Proportion of side effects and complications after thermoablation or LEEP | 3 - 5 years | questionnaire |
| Prevalence of HPV infection | 3 - 5 years | HPV self-test analysed by GeneXpert machine |
| VIA test-positive rate after 1- year follow-up of VIA-negative tests | 3 - 5 years | VIA/VILI is assessed by pelvic examination |
| Thermal ablation efficacy rate | 3 - 5 years | Thermal ablation efficacy rate will be assessed according to the biopsy proven CIN2+ rate after thermoablation treatment at the 6 and 12-month follow-up. The absence of CIN2+ will determine the success of the treatment in a patient who previously had a CIN2+ lesion. Adverses event : bleeding, complications, hospitalization |
| Acceptability rate of thermoablation | 3 years | To assess the acceptability of thermoablation, patients completed a questionnaire comprising different questions about treatment tolerance, pain and following side effects. Respondent were invited to rate answers on a likert scale of 1 (no accpetability) to 4 (high acceptability) |
| Sexual dysfunction score, score of anxiety and method of contraception after screening procedures, | 2 years | SF12, Asex, STAI 6 Y-form |
| Number of women screened with and without community health care workers. | 2 years | community health workers registre |
| Increase awareness on gynecological pathologies, including cervical cancer, sexually transmitted diseases and HIV, vaginal fistula in the community of the study area, | 3-5 years | questionnaire |
| VIA test-positive rate (HPV-positive women); | 3 - 5 years | VIA/VILI is assessed by pelvic examination |
Countries
Switzerland
Outcome results
None listed